Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ: LEGN )

35.78 +1.05 (+3.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Legend Biotech to Host R&D Day on October 18, 2021
From Legend Biotech
Via Business Wire
Week In Review: Everest Announces Two In-Licensings With Total Value Of $1 Billion
Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million deal. Shanghai Everest Medicines announced a $500 million two-part deal... 
Via Talk Markets
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
From Legend Biotech
Via Business Wire
Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
Will This 2020 Biotech IPO Crush the Market This Year?
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Product Safety Securities Market
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday morning, 54 companies achieved new highs for the year. Noteworthy Mentions: The largest company by market cap to set a new 52-week high was Costco... 
Via Benzinga
Legend Biotech Announces Advancement of Global Manufacturing Infrastructure
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
Via Benzinga
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings
From Legend Biotech
Via Business Wire
Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US
Legend Biotech Corporation (NASDAQ: LEGN) has announced that the FDA accepted for priority review the marketing application submitted by Janssen Biotech Inc... 
Via Benzinga
Exposures Product Safety
U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Legend Biotech to Present at the Jefferies Virtual Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
58 Biggest Movers From Yesterday
Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results. Ultralife Corporation (NASDAQ: ULBI)... 
Via Benzinga
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers Agenus Inc. (NASDAQ: AGEN) shares surged 33.4% to $4.35. Bristol-Myers Squibb Co and Agenus entered into a global exclusive license agreement, under which Bristol Myers... 
Via Benzinga
Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Week In Review: GenScript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
GenScript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to GenScript's Legend Biotech CAR-T subsidiary. Before the... 
Via Talk Markets
28 Stocks Moving in Friday's Pre-Market Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares rose 28.5% to $0.7451 in pre-market trading after the company reported better-than-expected Q1 sales. Bionano Genomics, Inc. (NASDAQ:... 
Via Benzinga
Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings
From Legend Biotech
Via Business Wire
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million... 
Via Talk Markets
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.